Role of erlotinib in the treatment of non-small cell lung cancer: Clinical outcomes in wild-type epidermal growth factor receptor patients

Drugs

Volumn 72, Issue SUPPL. 1, 2012, Pages 11-19

  Piperdi, Bilal ^a   Perez Soler, Roman ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PACLITAXEL; PANITUMUMAB; PLACEBO; PLATINUM; TIVANTINIB;

ADVANCED CANCER; ANEMIA; ANOREXIA; APOPTOSIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONFIDENCE INTERVAL; COUGHING; DIARRHEA; DISEASE CONTROL; DISEASE FREE SURVIVAL; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HAZARD RATIO; HUMAN; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; QUALITY OF LIFE; RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TUMOR BIOPSY; WILD TYPE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84862563024     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/1163018-S0-000000000-00000     Document Type: Review

References (39)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96 (Pubitemid 351521864)
2. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004; 350: 379-92 (Pubitemid 38101633)
3. Breathnach OS, Freidlin B, Conley B, et al. Twenty-two years of phase III trials for patients with advanced non-small- cell lung cancer: sobering results. J Clin Oncol 2001; 19: 1734-42 (Pubitemid 32230875)
4. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787-99 (Pubitemid 46606324)
5. Gridelli C, Maione P, Bareschino MA, et al. Erlotinib in the treatment of non-small cell lung cancer: current status and future developments.Anticancer Res 2010 Apr; 30 (4): 1301-10
6. Davies RL, Grosse VA, Kucherlapati R, et al. Genetic analysis of epidermal growth factor action: Assignment of human epidermal growth factor receptor gene to chromosome 7. Proc Natl Acad Sci U S A 1980; 77: 4188-92 (Pubitemid 10022574)
7. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159-67 (Pubitemid 30428195)
8. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-74
9. Perez-Soler R. HER1/EGFR targeting: refining the strategy. Oncologist 2004; 9: 58-67 (Pubitemid 38134014)
10. Ling YH, Li T, Yuan Z, et al. Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines. Mol Pharmacol 2007 Aug; 72 (2): 248-58 (Pubitemid 47124105)
11. Ling YH, Lin R, Perez-Soler R. Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small- cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK. Mol Pharmacol 2008 Sep; 74 (3): 793-806
12. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004 May 20; 350 (21): 2129-39 (Pubitemid 38637993)
13. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500 (Pubitemid 38720929)
14. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101: 13306-11 (Pubitemid 39209661)
15. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009 Aug; 28 Suppl. 1: S24-31
16. Ahn MJ, Park BB, Ahn JS, et al. Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? Clin Cancer Res 2008 Jun 15; 14 (12): 3860-6
17. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-67
18. Perez-Soler R. Erlotinib: recent clinical results and ongoing studies in non small cell lung cancer. Clin Cancer Res 2007 Aug 1; 13 (15 Pt 2): s4589-92
19. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al., National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005 Jul 14; 353 (2): 123-32 (Pubitemid 41058344)
20. Bezjak A, Tu D, Seymour L, et al., National Cancer Institute of Canada Clinical Trials Group Study BR.21. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2006 Aug 20; 24 (24): 3831-7 (Pubitemid 46630729)
21. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005 Jul 14; 353 (2): 133-44 (Pubitemid 41058345)
22. Reck M, van Zandwijk N, Gridelli C, et al. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol 2010 Oct; 5 (10): 1616-22
23. Spigel DR, Lin M, O'Neill V, et al. Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer. Cancer. 2008 Jun 15; 112 (12): 2749-55 (Pubitemid 351969220)
24. Yoshioka H, Hotta K, Kiura K, et al., Okayama Lung Cancer Study Group. A phase II trial of erlotinibmonotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705. J ThoracOncol. 2010 Jan; 5 (1): 99-104
25. Ciuleanu T, Stelmakh L, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012; Jan 24 [Epub ahead of print]
26. Fidias P, Novello S. Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010 Dec 1; 28 (34): 5116-23. Epub 2010 Nov 1. Review
27. Cappuzzo F, Ciuleanu T, Stelmakh L, et al., SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010 Jun; 11 (6): 521-9. Epub 2010 May 20
28. Brugger W, Kim JH, Hansen O, et al. Biomarker analyses from SATURN, a phase III placebo-controlled study of erlotinib as first-line maintenance therapy for advanced NSCLC. Eur J Cancer Supplements 2009; 7 (2): 559 (abstr P-9176)
29. Amann JM, Lee JW, Roder H, et al. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol 2010 Feb; 5 (2): 169-78
30. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007 Mar 1; 25 (7): 760-6 (Pubitemid 350002874)
31. Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008 Mar 20; 26 (9): 1472-8
32. Janne PA, Wang XF, Socinski MA, et al. Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. J Clin Oncol 2010; 28: 15s (suppl; abstr 7503)
33. Hesketh PJ, Chansky K, Wozniak AJ, et al. Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2. J Thorac Oncol 2008 Sep; 3 (9): 1026-31
34. Lee S, Rudd R, Khan I, et al. TOPICAL: Randomized phase III trial of erlotinib comparedwith placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy. J Clin Oncol 2010; 28: 15s (suppl; abstr 7504)
35. Lilenbaum R, Axelrod R, Thomas S, et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 2008 Feb 20; 26 (6): 863-9 (Pubitemid 351398077)
36. Kasahara K, Arao T, Sakai K, et al. Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma. Clin Cancer Res 2010 Sep15; 16 (18): 4616-24
37. Yap TA, Olmos D, Brunetto AT, et al. Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies. J Clin Oncol 2011, 29 (10): 1271-9. Epub 2011 Mar 7
38. Schiller JH, Akerley WL, Brugger W, et al. Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor- naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28: 18s (suppl; abstr LBA7502)
39. Hughes AN, O'Brien ME, Petty WJ, et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 2009 Mar 10; 27 (8): 1220-6